Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study

The Lancet Oncology

Volumn 13, Issue 4, 2012, Pages 403-411

  Kantarjian, Hagop ^a   Thomas, Deborah ^a   Jorgensen, Jeffrey ^a   Jabbour, Elias ^a   Kebriaei, Partow ^a   Rytting, Michael ^a   York, Sergernne ^a   Ravandi, Farhad ^a   Kwari, Monica ^a   Faderl, Stefan ^a   Rios, Mary Beth ^a   Cortes, Jorge ^a   Fayad, Luis ^a   Tarnai, Robert ^c   Wang, Sa A ^a   Champlin, Richard ^a   Advani, Anjali ^b   O'Brien, Susan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Pharmaceutical Product Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIFUNGAL AGENT; BUSULFAN; CD22 ANTIGEN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DIPHENHYDRAMINE; ETOPOSIDE; FLUDARABINE; HYDROCORTISONE; HYDROXYUREA; INOTUZUMAB OZOGAMICIN; MELPHALAN; METHOTREXATE; PARACETAMOL; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLE DERIVATIVE; RITUXIMAB; STEROID; THIOTEPA; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANOREXIA; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BILIRUBIN BLOOD LEVEL; BLAST CELL; BLOOD CELL COUNT; BLOOD DONOR; BONE MARROW SUPPRESSION; CANCER INFILTRATION; CANCER MORTALITY; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 4; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSTIPATION; DIARRHEA; DIPLOIDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG RESPONSE; ECOG PERFORMANCE STATUS; EVENT FREE SURVIVAL; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOTENSION; INDUCTION CHEMOTHERAPY; INFECTION; LEUKEMIA INFILTRATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER TOXICITY; MINIMAL RESIDUAL DISEASE; MIXED INFECTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RECURRENCE RISK; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNRELATED DONORS; VEIN OCCLUSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD22; CHILD; ENEDIYNES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84862786326     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70386-2     Document Type: Article

References (32)

1. Pui CH, Evans WE Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166-178.
2. Pui CH, Carroll W, Meshinchi S, Arceci R Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011, 29:551-565.
3. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000, 14:2223-2233.
4. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German multicenter study group for adult ALL (GMALL). Hematol Oncol Clin North Am 2000, 14:1307-1325.
5. Bassan R, Hoelzer D Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011, 29:532-543.
6. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia. Cancer 2010, 116:1165-1176.
7. Goekbuget N, Hoelzer D Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009, 46:64-75.
8. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacology study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003, 102:2379-2386.
9. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004, 103:784-789.
10. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and desamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004, 101:2788-2801.
11. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009, 360:2730-2741.
12. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatnib mesylate. Blood 2004, 103:4396-4407.
13. Ravandi F, O'Brien S, Thomas D, et al. First report of phase II study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood 2010, 116:2070-2077.
14. Bassan R, Rossi G, Pogliani M, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010, 28:3644-3652.
15. Schultz K, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 2009, 27:5175-5181.
16. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006, 106:1569-1580.
17. Gokbuget N, Hoelzer D Rituximab in the treatment of adult ALL. Ann Hematol 2006, 85:117-119.
18. Rizzieri D, Johnson J, Byrd J, et al. Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B (Calgh) study 10002. Blood 2010, 116(suppl):858. (abstr).
19. Thomas D, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de-novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010, 28:3880-3889.
20. Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003. Blood 2010, 116(suppl):170. (abstr).
21. Huguet F, Leguay T, Rafoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009, 27:911.
22. Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma 2011, 52:325-327.
23. Raetz E, Cairo M, Borowitz M, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group pilot study. J Clin Oncol 2008, 26:3756-3762.
24. Topp M, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011, 29:2493-2498.
25. Topp MS, Goekbuget N, Zugmaier G, et al. Clinical activity of the anti-CD19 BiTE blinatumomab in patients with relapsed/refractory b-precursor acute lymphoblastic leukemia: interim results of a phase 2 study. European Hematology Association 16th Congress; London, UK; June 9-12, 2011. Abstract 844.
26. Thorson J, Sievers E, Ahlert J, et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr Pharm Des 2000, 6:1841-1879.
27. Advani A, Coiffier B, Czuczman M, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of b-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010, 28:2085-2093.
28. Di Joseph J, Dougher M, Kalyandrug L, et al. Antitumor efficacy of a combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006, 12:242-249.
29. Thall F, Simon R, Estey EH Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 1995, 14:357-379.
30. Kebraie P, Wilhelm K, Ravandi F, et al. Inotuzumab ozogamicin (IO) is an effective salvage therapy that allows for allogeneic hematopoietic stem cell transplantation (HSCT) in remission in patients with advanced acute lymphoblastic leukemia (ALL). Blood 2011, 118(suppl):3102. (abstr).
31. Thomas D, Kantarjian H, Smith T, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia. Cancer 1999, 86:1216-1230.
32. Rousselot P, Cayuela JM, Hayette S, et al. Dasatinib (Sprycel®) and low intensity chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL (EWALL-PH-01): kinetic of response, resistance and prognostic significance. Blood 2010, 116(suppl):172. (abstr).